Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
dry eye disease
Biotech
FDA rejects Aldeyra eye disease candidate for 3rd time
AbbVie has an option agreement for reproxalap, making Aldeyra eligible for a $100 million payment if the FDA approves the drug in dry eye disease.
Gabrielle Masson
Mar 17, 2026 11:12am
Aldeyra dry eye disease decision hit by FDA delay
Dec 16, 2025 11:55am
Théa pens $280M deal for Iolyx's phase 3-ready eye disease drug
Dec 3, 2025 8:25am
Stuart sees dry eye disease drug fail ph. 3 study, plans another
Jun 24, 2025 9:26am
Aldeyra posts hit, miss for dry eye drug, plans FDA filing
May 6, 2025 7:05am
Aldeyra’s dry eye drug suffers second FDA rejection
Apr 3, 2025 8:46am